In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Clinical Trials - Diseases by specialty group
Lymphoma 5
-
Protocol ID
- Associated disease
- Title
-
IIT-HOAG-PAVIR
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Other Lymphoma
- PAViR: Using Virtual Reality to Increase Physical Activity in Youths with Cancer
-
COG-AALL1732
- Non-Hodgkin's Lymphoma
- Other Lymphoma
- A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
-
COG-APEC1621SC
- Non-Hodgkin's Lymphoma
- NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
IIT-MOSKOP-MABD
- Non-Hodgkin's Lymphoma
- Other Lymphoma
- Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation with Alpha/Beta T-Cell and B-Cell Depletion for Patients with Hematologic Malignancies with Targeted ATG Dosing Pilot Study, IDE 13641
-
MAGIC-LRPEDS
- Non-Hodgkin's Lymphoma
- Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD